AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05150431
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is normal saline 2ml, which is equal to the volume of parecoxib solution. Placebo will be injected to placebo group 15 minutes before the end of the surgery.
Trial: NCT04816916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered TID with food
Trial: NCT05341401
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It is a corticosteroid used as a standard therapy for management of ulcerative colitis
Trial: NCT05922384
Drug: KL-7SHRNA injection solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients continue to receive HAART throughout treatment until meet the criteria of interruption of HAART.
Trial: NCT06213987
Drug: 0.025% Tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total duration of 8 weeks.
Trial: NCT05292196
Drug: TQC3721 suspension for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
Trial: NCT05292196
Drug: TQC3721 suspension placebo for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
Trial: NCT00001989
Drug: Trichosanthin
RxNorm normalized name: Trichosanthes kirilowii fruit rind
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00240799
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05684744
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients will receive methotrexate in a dose of 0.2- 0.4 mg/kg/week for 12 weeks
Trial: NCT06204952
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In patients with facet joint syndrome, placebo drug is administered at a dosage of 1 tablet three times a day for 12 weeks.
Trial: NCT04927247
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug.
Trial: NCT06417697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule formulation
Trial: NCT04732065
Drug: ONC206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally (PO)
Trial: NCT06487845
Drug: BAY3283142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR tablets, oral
Trial: NCT06487845
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to BAY3283142
Trial: NCT03520751
Drug: scAAV1.tMCK.NTF3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gene vector
Trial: NCT05593445
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Trial: NCT04489134
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
Trial: NCT04489134
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a 2 mg dose of LCP-tacro (Envarsus®)
Trial: NCT04489134
Drug: Treament C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
Trial: NCT06727890
Drug: Danshen Dripping Pill
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danshen Dripping Pill, 10 pills once, three times a day
Trial: NCT06727890
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 10 pills once, three times a day
Trial: NCT04805671
Drug: ADG20
RxNorm normalized name: Adintrevimab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of ADG20
Trial: NCT04805671
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of normal saline
Trial: NCT04652557
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no active component
Trial: NCT05555862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo intra-anal suppository
Trial: NCT05345457
Drug: Azithromycin Pill
RxNorm normalized name: azithromycin Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin will be dosed as single 500 mg dose (2-250mg oral tablets) administered immediately following randomization, yet prior to discharge to home, followed with 1-250mg oral tablet daily for 4 additional days (for a total of 5 days).
Trial: NCT05279859
Drug: ERAS-007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05279859
Drug: ERAS-601
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06358872
Drug: Azithromycin for Oral Suspension
RxNorm normalized name: Azithromycin for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin will be administered as a single dose, in oral suspension form for children. The dose will be calculated by age or height depending on the child's age Both dosing cups and syringes will be used to administer treatment. For children too young to drink out of a dosing cup, a 1 ml or 5 ml syringe will be used, and the calculated dose will be rounded upwards to the nearest 0.2 ml.
Trial: NCT05852093
Drug: Celecoxib+Buprenorphine Transdermal Patch
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: NSAIDs+narcotic analgesics
Trial: NCT05852093
Drug: Celecoxib+Buprenorphine Transdermal Patch+Tizanidine
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: NSAIDs+narcotic analgesics+Skeletal Muscle Relaxant
Trial: NCT06306131
Drug: Meloxicam 15 milligram
RxNorm normalized name: meloxicam 15 MILLIGRAM In 1 TABLET ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study design is an open label randomized single blind clinical trial in which each participant will receive placebo two tablets 48 hours apart in their first menstrual cycle and then levonorgestrel plus meloxicam 48 hours apart in their subsequent menstrual cycle. We will compare the interval from taking the first dose of medication to the development of a functioning corpus luteum based on the shift in the ratio of urinary estrone-3-glucuronide(EC) / pregnanediol-3-glucuronide (PDG).
Trial: NCT05507489
Drug: Jinzhen oral liquid or Jinhuaqinggan granules
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinzhen oral liquid, for 3 years old, 10 ml once, twice a day; for 4 to 7 years old, 10 ml a time, 3 times a day; for 8 to 18 years old, 15 ml a time, 3 times a day.The dosage and usage of Jinhua Qinggan granules were determined by the researcher according to the patient's condition. The drugs were medicated for 14 days.
Trial: NCT00534898
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05652647
Drug: Oral [14C]PF-07081532
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of \[14C\]PF-07081532, will be administered as a liquid formulation in study period 1.
Trial: NCT05652647
Drug: Oral PF-07081532 and IV [14C]PF-07081532
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In study period 2: a single, oral, unlabeled dose of PF-07081532 will be administered as a liquid formulation. Approximately 1 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-07081532 will be administered via intravenous infusion.
Trial: NCT06081153
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm description.
Trial: NCT04914429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered as a SC injection.
Trial: NCT06609525
Drug: CTO0303-A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eye drop, 1 drop 3 times (every 5 minutes) a day
Trial: NCT06609525
Drug: CTO0303-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eye drop, 1 drop 3 times (every 5 minutes) a day
Trial: NCT05157269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two matching placebo tablets administered orally twice daily for 5 days
Trial: NCT06610487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered.
Trial: NCT06609980
Drug: autologous fecal matter transplant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous fecal matter transplant will be used to re-seed the child's gut with his or her own personalized microbiome composition which was preserved prior to antibiotics use.
Trial: NCT05117060
Drug: LEO 152020 tablet
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LEO 152020 is a small drug molecule which can bind to the histamine 4 receptor (H4R) and prevent histamine from binding to the receptor. LEO 152020 is a tablet for oral administration.
Trial: NCT05117060
Drug: LEO 152020 placebo tablet
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEO 152020 placebo tablet contains the same excipients in the same concentration as LEO 152020 tablet, except that it does not contain the medical ingredient LEO 152020. LEO 152020 placebo is a tablet for oral administration.
Trial: NCT05241938
Drug: Prostaglandin analogue eye drops
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin analogue eye drops will be prescribed to be used continuously once a day in the fellow eye.
Trial: NCT05630820
Drug: Bepirovirsen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepirovirsen will be administered.
Trial: NCT04357951
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A pill placebo serves as an active comparator. It will be paired with 4 sessions of behavior therapy.
Trial: NCT00301587
Drug: Norgestimate-ethinyl estradiol, with or without folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02355054
Drug: C-11 Choline PET Imaging
RxNorm normalized name: choline C-11
DrugBank: Choline C-11 (DB09563)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive IV injection of C-11 Choline followed by imaging from the base of the brain to the upper thigh on a PET/CT or a PET/MRI scanner
Trial: NCT05379036
Drug: prescribing anapproved drug, examination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Blood test to assess serum zonulin levels;~* Esophagogastroduodenoscopyand colonoscopy with biopsy from the small and large intestine followed by histological examination;~* Stool sample collection to assess short-chain fatty acid levels and the composition of the gut microbiota.~Then the patients were prescribed therapy with the approved drug trimebutin (trimedat) with placebo or trimebutine with rebamipide or rebamipide with placebo for 2 months.
Trial: NCT05152420
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VMX-C001 matched placebo
Trial: NCT06153069
Drug: Short-course regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, \>70kg 2000mg daily; ethambutol ≤50kg 750mg daily, \>50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (0 or 9 weeks based on the radiological manifestations), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally.
Trial: NCT00000689
Drug: Doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000689
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00000689
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00000689
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05652855
Drug: MHB088C for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MHB088C for Injection, an antibody drug-conjugated molecule (ADC)
Trial: NCT06153069
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, \>70kg 2000mg daily; ethambutol ≤50kg 750mg daily, \>50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (18 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally.
Trial: NCT06449235
Drug: Sulphonylureas
RxNorm normalized name: metformin and sulfonylureas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical Name: Sulphonylureas Class: Sulphonylureas~Mechanism of Action:~Stimulates insulin release from pancreatic beta cells. Enhances the sensitivity of beta cells to glucose. Reduces hepatic glucose production. Increases peripheral glucose uptake and utilization. Administration: Typically administered once or twice daily, depending on the specific medication and patient needs.
Trial: NCT06449235
Drug: Other DPP4-i
RxNorm normalized name: Other i.v. solution additives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical Names: Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Alogliptin Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors~Mechanism of Action:~Inhibits DPP-4 enzyme, thereby increasing incretin levels. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Improves β-cell function of the pancreas. Reduces hepatic glucose output. Administration: Typically administered orally once daily. Dosage may vary depending on the specific medication and patient needs.
Trial: NCT06449235
Drug: Thiazolidinediones
RxNorm normalized name: Thiazolidinediones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical Name: Thiazolidinediones (e.g., Pioglitazone, Rosiglitazone) Class: Thiazolidinediones (TZDs)~Mechanism of Action:~Activates peroxisome proliferator-activated receptor-gamma (PPAR-γ) in adipose tissue, muscle, and liver.~Increases insulin sensitivity in peripheral tissues. Enhances glucose uptake and utilization in muscle and adipose tissue. Reduces hepatic glucose production. Administration: Administered orally, typically once daily. Dosage may vary based on the specific medication and patient response.
Trial: NCT06449235
Drug: Alpha-Glucosidase Inhibitor
RxNorm normalized name: Alpha-glucosidase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical Name: Alpha-Glucosidase Inhibitors (e.g., Acarbose, Miglitol) Class: Alpha-Glucosidase Inhibitors~Mechanism of Action:~Inhibits alpha-glucosidase enzymes in the small intestine. Delays the breakdown and absorption of complex carbohydrates. Reduces postprandial blood glucose levels. Administration: Administered orally, typically taken with the first bite of each main meal. Dosage may vary based on the specific medication and patient response.
Trial: NCT06449235
Drug: Receptor Agonists (GLP1RA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical Name: GLP-1 Receptor Agonists (GLP1RA) (e.g., Exenatide, Liraglutide, Dulaglutide, Semaglutide) Class: Glucagon-Like Peptide-1 Receptor Agonists~Mechanism of Action:~Activates GLP-1 receptors. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Slows gastric emptying. Promotes satiety and reduces food intake. Improves β-cell function of the pancreas. Administration: Administered via subcutaneous injection, with frequency varying from twice daily to once weekly, depending on the specific medication.
Trial: NCT05935280
Drug: A967079
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific antagonist of the TRPA1 ion channel
Trial: NCT05086276
Drug: FX-322
RxNorm normalized name: Prevail-FX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT05086276
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05946876
Drug: XH-S003 (A)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IP: XH-S003 IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
Trial: NCT00243763
Drug: TKI258
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05308160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease. This is a principal investigator initiate study. This study is supported by Liver Disease Prevention \& Treatment Research Foundation. Dapagliflozin will be provided free of charge by AstraZeneca.
Trial: NCT05180500
Drug: Q-Griffithsin
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q-Griffithsin is derived from Griffithsin (GRFT) which is a non-glycosylated protein consisting of 121 amino acids. Q-GRFT contains a single amino acid substitution, M78Q variant, resistant to oxidation yet maintains the parent molecule's pharmacological profile.
Trial: NCT05180500
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A matched vehicle solution manufactured and dispensed in same applicators as the active comparator.
Trial: NCT04708184
Drug: GLPG3970 oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG3970 for oral administration
Trial: NCT04708184
Drug: GLPG3970 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG3970 for oral administration
Trial: NCT05586802
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This will be an active comparator for 26 weeks in Group 2 - Arm C
Trial: NCT04767113
Drug: Heparin sodium
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For infants without thrombosis at enrollment, heparin 1 U/kg/h/line for term infants was used and 0.5 U/kg/h/line for preterm infants. The speed of infusion was 0.5ml/h.~For infants with thrombosis at enrollment, heparin 10-15 U/kg/h for term infants was used with a target activated partial thromboplastin time 60-70s. Other interventions were at the clinical team's discretion under the local protocol.
Trial: NCT04767113
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For infants enrolled, normal saline was infused at the corresponding speed.
Trial: NCT05145140
Drug: Standardized Western Medicine Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized Western Medicine Treatment includes hypoglycemic, debridement and anti infection treatments.
Trial: NCT05145140
Drug: Tangningtongluo tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc. It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.The participants in this arm use tablet.
Trial: NCT05145140
Drug: Tangningtongluo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc. It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.The participants in this arm use cream.
Trial: NCT04706559
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical corticosteroid, topical tacrolimus, an oral antihistamine and emollients as per atopic dermatitis treatment guidelines.
Trial: NCT05460832
Drug: MBS2320 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT05460832
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT05138796
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match TP-05 (lotilaner oral capsules)
Trial: NCT06723197
Drug: vonoprazan+amoxicillin+tetracycline+bismuth
RxNorm normalized name: bismuth biskalcitrate / metronidazole / tetracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug combinations for quadruple regimens: vonoprazan+amoxicillin+tetracycline+bismuth
Trial: NCT06704334
Drug: Ginkgo leaf dropping pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT06727981
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention involves the administration of standard chemotherapy alone.
Trial: NCT06222268
Drug: Placebo only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered in the same way as active drugs through the vaporizer. Placebo cannabis material obtained through National Institute of Drug Abuse (NIDA) contains 0mg THC and 0mg CBD
Trial: NCT06222268
Drug: THC:CBD 1:1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis containing 2.5mg of THC and 2.5mg of CBD is delivered through a vaporizer.
Trial: NCT06222268
Drug: THC:CBD 1:10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis containing 2.5mg THC and 25mg CBD is delivered through a vaporizer.